ES2144424T3 - Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige. - Google Patents

Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige.

Info

Publication number
ES2144424T3
ES2144424T3 ES92920757T ES92920757T ES2144424T3 ES 2144424 T3 ES2144424 T3 ES 2144424T3 ES 92920757 T ES92920757 T ES 92920757T ES 92920757 T ES92920757 T ES 92920757T ES 2144424 T3 ES2144424 T3 ES 2144424T3
Authority
ES
Spain
Prior art keywords
ige
vaccine
mediated
treatment
allergic reactions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92920757T
Other languages
English (en)
Other versions
ES2144424T5 (es
Inventor
Lars T Hellman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20383848&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2144424(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of ES2144424T3 publication Critical patent/ES2144424T3/es
Application granted granted Critical
Publication of ES2144424T5 publication Critical patent/ES2144424T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/801—Drug, bio-affecting and body treating compositions involving antibody or fragment thereof produced by recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/862—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

LA INVENCION SE REFIERE A UNA VACUNA, PREFERENTEMENTE PARA SERES HUMANOS, CONTRA LAS REACCIONES ALERGICAS MEDIADAS POR LA IGE. LA VACUNA CONTIENE UNA PROTEINA QUE TIENE TODA LA SECUENCIA DE AMINOACIDOS DE LOS DOMINIOS CONSTANTES CH2-CH3 DE LA CADENA EPSILON DE LA MOLECULA IGE O UNA UNIDAD ESTRUCTURALMENTE ESTABLE DE DICHA SECUENCIA DE AMINOACIDOS, EN DONDE LA PROTEINA SE PUEDE ENCONTRAR OPCIONALMENTE ACOPLADA A UNA O MAS PROTEINAS DE SOPORTE HETEROLOGAS Y OPCIONALMENTE CONTIENEN UN AUXILIAR. LA VACUNA SE INYECTA, CON O SIN AUXILIAR, PARA AUMENTAR LA CONCENTRACION DE ANTICUERPOS ENDOGENOS CONTRA LA IGE EN EL PLASMA DE SUJETOS ALERGICOS. EN LA PRACTICA, LA VACUNA SE PUEDE UTILIZAR CONTRA TODOS LOS TIPOS DE ALERGIAS MEDIADAS POR LA IGE PUESTO QUE LOS ANTICUERPOS NO DEPENDEN DE LA ESPECIFICIDAD DEL ANTIGENO DE LA MOLECULA IGE PERO REDUCIRA LA RESERVA TOTAL DE IGE DEL SUJETO. POR TANTO LA VACUNA ES UTIL PARA EL TRATAMIENTO DE SUJETOS QUE PADECEN DIFERENTES TIPOS DE ALERGIAS MEDIADAS POR LA IGE.LAS CONCENTRACIONES AUMENTADAS DE ANTICUERPOS CONTRA LA IGE REDUCEN LA RESERVA LIBRE DE IGE ESPECIFICA AL ANTIGENO, CON LO QUE REDUCE EN GRAN MEDIDA EL RIESGO DE UNA LIBERACION MEDIADA POR EL ALERGENO DE SUSTANCIAS FISIOLOGICAMENTE MUY ACTIVAS ALMACENADAS O PRODUCIDAS JUNTO CON LA LIBERACION DE GRANULOS DE LAS CELULAS MASTETICAS Y LEUCOCITOS BASOFILICOS.
ES92920757T 1991-09-26 1992-09-25 Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige. Expired - Lifetime ES2144424T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9102808 1991-09-26
SE9102808A SE9102808L (sv) 1991-09-26 1991-09-26 Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner

Publications (2)

Publication Number Publication Date
ES2144424T3 true ES2144424T3 (es) 2000-06-16
ES2144424T5 ES2144424T5 (es) 2008-03-01

Family

ID=20383848

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92920757T Expired - Lifetime ES2144424T5 (es) 1991-09-26 1992-09-25 Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige.

Country Status (16)

Country Link
US (1) US5653980A (es)
EP (1) EP0666760B2 (es)
JP (2) JP3583421B2 (es)
KR (1) KR100263359B1 (es)
AT (1) ATE189960T1 (es)
AU (1) AU677573B2 (es)
CA (1) CA2117193C (es)
DE (1) DE69230733T3 (es)
DK (1) DK0666760T4 (es)
ES (1) ES2144424T5 (es)
FI (1) FI107880B (es)
GR (1) GR3033272T3 (es)
HU (1) HU218899B (es)
RU (1) RU2120805C1 (es)
SE (1) SE9102808L (es)
WO (1) WO1993005810A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
AU707083B2 (en) * 1993-08-26 1999-07-01 Bavarian Nordic Inc. Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
JP3825798B2 (ja) * 1994-01-18 2006-09-27 ジェネンテク，インコーポレイテッド ＩｇＥアンタゴニストを用いる寄生虫感染症の治療法
FR2715304B1 (fr) * 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
HUP9901109A3 (en) * 1996-03-01 1999-11-29 Novartis Ag Peptide immunogens for vaccination against and treatment of allergy
PL194221B1 (pl) * 1997-04-15 2007-05-31 Pharmexa As Zmodyfikowana cząsteczka ludzkiego TNFalfa, dimery, oligomery lub multimery zmodyfikowanej cząsteczki ludzkiego TNFalfa, wyizolowana cząsteczka DNA, wektor, wektor ekspresyjny, komórka gospodarza, sposób wytwarzania zmodyfikowanej cząsteczki ludzkiego TNFalfa, szczepionki przeciwko TNFalfa oraz zastosowanie przynajmniej jednej zmodyfikowanej cząsteczki ludzkiego TNFalfa
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
US6504013B1 (en) 2000-02-01 2003-01-07 Idexx Laboratories, Inc. Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
US6734287B1 (en) 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
EP1621209A3 (en) * 1998-11-02 2006-04-19 Resistentia Pharmaceuticals AB Vaccines based on domains of chimeric immunoglobulin E peptides
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US6602719B1 (en) 1999-03-26 2003-08-05 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US6511814B1 (en) 1999-03-26 2003-01-28 Idexx Laboratories, Inc. Method and device for detecting analytes in fluids
US6887472B2 (en) 2000-08-30 2005-05-03 Pfizer Inc. Anti-IgE vaccines
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
EP1497654A4 (en) * 2001-08-13 2006-06-07 Chen Swey Shen Alex IMMUNOGLOBULIN E VACCINES AND METHODS OF USE
CA2495251C (en) 2002-08-14 2018-03-06 Macrogenics, Inc. Fc.gamma.riib-specific antibodies and methods of use thereof
EP1545607B1 (en) * 2002-09-05 2008-11-19 Resistentia Pharmaceuticals AB Allergy vaccines
US20050026881A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease
US20090263381A1 (en) * 2003-07-31 2009-10-22 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
HUE030269T2 (en) 2006-06-26 2017-04-28 Macrogenics Inc FC RIIB-specific antibodies and methods for their use
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
EP2865389A1 (en) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
SG174161A1 (en) * 2009-02-25 2011-11-28 Tsewen Chang ANTI-CemX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES
EP2942061A3 (en) * 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
US9587034B2 (en) 2012-04-20 2017-03-07 Academia Sinica Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains
JP5918851B2 (ja) * 2012-06-18 2016-05-18 日本全薬工業株式会社 ＩｇＥペプチドワクチン
US20150004161A1 (en) * 2013-07-01 2015-01-01 University Of Maryland Fc Coupled Compositions and Methods of Their Use
CN111741768A (zh) 2017-10-31 2020-10-02 合一生技股份有限公司 治疗IgE介导的过敏性疾病

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8616166D0 (en) * 1986-07-02 1986-08-06 Research Corp Ltd Polypeptide competitor
GB8727045D0 (en) * 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
AU618317B2 (en) * 1987-12-31 1991-12-19 Tanox Biosystems, Inc. Unique antigenic epitopes on ige-bearing b lymphocytes
GB8910263D0 (en) * 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) * 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment

Also Published As

Publication number Publication date
JP3583421B2 (ja) 2004-11-04
EP0666760A1 (en) 1995-08-16
HU9400845D0 (en) 1994-06-28
EP0666760B1 (en) 2000-03-01
DE69230733T3 (de) 2008-05-21
CA2117193C (en) 2008-06-17
FI941193A (fi) 1994-03-14
JPH06510768A (ja) 1994-12-01
AU677573B2 (en) 1997-05-01
DE69230733D1 (de) 2000-04-06
HU218899B (hu) 2000-12-28
AU2676592A (en) 1993-04-27
ES2144424T5 (es) 2008-03-01
SE9102808L (sv) 1993-03-27
KR100263359B1 (ko) 2000-08-01
JP2004231663A (ja) 2004-08-19
US5653980A (en) 1997-08-05
FI107880B (fi) 2001-10-31
SE9102808D0 (sv) 1991-09-26
CA2117193A1 (en) 1993-04-01
RU2120805C1 (ru) 1998-10-27
FI941193A0 (fi) 1994-03-14
GR3033272T3 (en) 2000-09-29
DK0666760T4 (da) 2008-01-21
WO1993005810A1 (en) 1993-04-01
DE69230733T2 (de) 2000-08-03
HUT69782A (en) 1995-09-28
DK0666760T3 (da) 2000-07-31
EP0666760B2 (en) 2007-10-10
ATE189960T1 (de) 2000-03-15

Similar Documents

Publication Publication Date Title
ES2144424T3 (es) Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige.
DK0526544T3 (da) Terapeutiske anvendelser af actinbindende forbindelser
EA199800946A1 (ru) Концентрированный препарат антител
ES2227527T3 (es) Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada.
EA199900553A1 (ru) Чрескожная терапевтическая система
DE60032486D1 (de) Prion protein peptide und deren verwendung
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
ES2119411T5 (es) Combinaciones de proteinas y anticoagulantes tromboliticamente activos, y usos de los mismos.
PT866720E (pt) Proteina ob para aumentar a massa do tecido mole
DE69635582D1 (de) Diagnostika und behandlungen von peridontalen erkrankungen
BR0013353A (pt) Combinação de substância ativa com clonidina
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
EA200400134A1 (ru) Терапевтический агент
AR004093A1 (es) El uso de una proteina derivada de una quimioquina de mamifero y un medicamento util para movilizar celulas tronco hematopoyeticas.
ES2164699T3 (es) Anticuerpo lo-cd2a y usos del mismo para inhibir la activacion y la proliferacion de las celulas t.
DK0837672T3 (da) Præparationer og fremgangsmåder til behandling af T-cellemedierede sygdomme
ES2180750T3 (es) Conjugado de un principio activo, un polieter y, en caso dado, una proteina nativa no considerada como exogena.
ES2154761T3 (es) Mejora de la tolerancia de beta-aminoacidos farmaceuticamente activos.
ES2147200T3 (es) Uso de un veneno de himenopteros para la fabricacion de un medicamento para tratar infecciones por virus de adn.
ES2091159B1 (es) Antigeno recombinante, rsm14, procedente de schistosoma mansoni, su obtencion y utilizacion.
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
RU94039630A (ru) Устройство для воздействия на биологический объект
DK0820308T3 (da) Konjugat til behandling af inflammatoriske sygdomme
EA200000717A1 (ru) Устройство для профилактики и лечения заболеваний органов поясничной и тазобедренной части организма

Legal Events

Date Code Title Description
FA2A Application withdrawn

Effective date: 19940427

FG2A Definitive protection

Ref document number: 666760

Country of ref document: ES